Current Developments in Pharmacogenomics of Multiple Sclerosis

被引：5
|
作者：
Carlson, Rebecca J. [1 ,2 ]
Doucette, J. Ronald [2 ,3 ,4 ]
Nazarali, Adil J. [1 ,4 ,5 ]
机构：
[1] Univ Saskatchewan, Coll Pharm & Nutr, Mol Cell Biol Lab, Saskatoon, SK S7N 5C9, Canada
[2] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5C9, Canada
[3] Univ Saskatchewan, Dept Anat & Cell Biol, Coll Med, Saskatoon, SK S7N 5C9, Canada
[4] City Hosp, Cameco Multiple Sclerosis Neurosci Res Ctr, Saskatoon, SK, Canada
[5] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5E2, Canada
来源：
CELLULAR AND MOLECULAR NEUROBIOLOGY | 2014年 / 34卷 / 08期
基金：
加拿大健康研究院;
关键词：
Pharmacogenomics; Multiple sclerosis; Interferon-beta; Glatiramer acetate; SNPs; Genome-wide association studies; INTERFERON-BETA THERAPY; GLATIRAMER ACETATE; GENE; SUSCEPTIBILITY; POLYMORPHISMS; MARKERS;
D O I：
10.1007/s10571-014-0095-0
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Pharmacogenomics has a significant potential to impact how we treat diseases. It involves targeting genetically identifiable populations with therapeutic interventions that promises to yield immediate positive health outcomes with lower or no side effects. The 'trial and error' method of treatment will no longer be necessary with the successful implementation of personalized medicine. The following is an overview of some new developments in pharmacogenomics of multiple sclerosis, and how it has the potential to improve future treatment.
引用
收藏
页码：1081 / 1085
页数：5
相关论文
共 50 条
  • [1] Current Developments in Pharmacogenomics of Multiple Sclerosis
    Rebecca J. Carlson
    J. Ronald Doucette
    Adil J. Nazarali
    Cellular and Molecular Neurobiology, 2014, 34 : 1081 - 1085
  • [2] Pharmacogenomics of multiple sclerosis
    Favorova, O.
    Kulakova, O.
    Tsareva, E.
    Lvovs, D.
    Favorov, A.
    Vandenbroeck, K.
    Boyko, A.
    FEBS JOURNAL, 2013, 280 : 343 - 343
  • [3] Pharmacogenomics of Multiple Sclerosis: A Systematic Review
    Hocevar, Keli
    Ristic, Smiljana
    Peterlin, Borut
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [4] IFN-β pharmacogenomics in multiple sclerosis
    Vandenbroeck, Koen
    Urcelay, Elena
    Comabella, Manuel
    PHARMACOGENOMICS, 2010, 11 (08) : 1137 - 1148
  • [5] Current developments in MRI for assessing rodent models of multiple sclerosis
    Alomair, Othman I.
    Smith, Maree T.
    Brereton, Ian M.
    Galloway, Graham J.
    Kurniawan, Nyoman D.
    FUTURE NEUROLOGY, 2014, 9 (04) : 487 - 511
  • [6] Use of pharmacogenomics in clinical trials for multiple sclerosis
    Martin, R
    JOURNAL OF NEUROCHEMISTRY, 2002, 81 : 81 - 81
  • [7] Pharmacogenomics of multiple sclerosis: in search for a personalized therapy
    Martinez-Forero, Ivan
    Pelaez, Antonio
    Villoslada, Pablo
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (17) : 3053 - 3067
  • [8] Multiple sclerosis: pharmacogenomics and personalised drug treatment
    V. Annibali
    G. Ristori
    S. Cannoni
    S. Romano
    A. Visconti
    A. Ghazaryan
    L. Figà Talamanca
    M. Salvetti
    R. Mechelli
    Neurological Sciences, 2006, 27 : s347 - s349
  • [9] Multiple sclerosis pharmacogenomics Maximizing efficacy of therapy
    Pappas, Derek J.
    Oksenberg, Jorge R.
    NEUROLOGY, 2010, 74 (01) : S62 - S69
  • [10] Multiple sclerosis: pharmacogenomics and personalised drug treatment
    Annibali, V.
    Ristori, G.
    Cannoni, S.
    Romano, S.
    Visconti, A.
    Ghazaryan, A.
    Talamanca, L. Figa
    Salvetti, M.
    Mechelli, R.
    NEUROLOGICAL SCIENCES, 2006, 27 (Suppl 5) : S347 - S349
12345